Howard W. Bruckner

Skin Cancer Foundation — United States

Medicine · Health Sciences

40h-index6.4kcitations295works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(48), Ovarian cancer diagnosis and treatment(37), Colorectal Cancer Treatments and Studies(34), Gastric Cancer Management and Outcomes(30), Cancer Genomics and Diagnostics(20)

Publications294 total

Enhancing Toxicity Reporting With Objective Measures and Contemporary Tools
JCO Oncology Practice·2025
Cholangiocarcinoma, sequential chemotherapy, and prognostic tests
Frontiers in Oncology·2024Open Access
Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast
Frontiers in Molecular Medicine·2023· 1 citedOpen Access
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times
PLoS ONE·2022· 3 citedOpen Access
Blood Tests Predict Safe Survival of Elderly with Resistant GI Cancers
Journal of Geriatric Oncology·2021· 1 cited
Tumor protein p53 mutation in archived tumor samples from a 12‑year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long‑term survival with DeltaRex‑G: A case report and literature review
Molecular and Clinical Oncology·2021· 10 citedOpen Access
Moderate dose serial therapy for aged and resistant patients with cholangiocarcinomas.
Journal of Clinical Oncology·2021
Blood tests to predict one- to two-year survival of patients with difficult cancers.
Journal of Clinical Oncology·2021
Long Term Survival Following DeltaRex-G/DeltaVax Tumor-Targeted Gene Therapy for Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone
Clinics in Oncology·2021· 6 citedOpen Access
P-373 Moderate dose chemotherapy retains efficacy and improves safety in conjunction with high dose ascorbic acid (HDAA)
Annals of Oncology·2020Open Access
P-372 Safe moderate dose regimens retain full survival benefits for aged patients with and without resistant gastrointestinal cancers
Annals of Oncology·2020Open Access
Survival and prognostic tests in a real-world phase II experience with a safe, moderate-dose, sequential chemotherapy (CT) algorithm (ALGO) for metastatic pancreatic adenocarcinoma (PANC).
Journal of Clinical Oncology·2020· 1 cited
MODERATE DOSE SEQUENTIAL CHEMOTHERAPY (CT) ALGORITHMS (ALGOS) FOR THE ELDERLY WITH AND WITHOUT RESISTANT CANCERS (R-C)
Journal of Geriatric Oncology·2019· 1 cited
MODERATE SEQUENTIAL THIRD- TO FOURTH-LINE CHEMOTHERAPY (CT) ALGORITHMS (ALGO) FOR THE ELDERLY WITH RESISTANT COLORECTAL CANCER (R-CRC)
Journal of Geriatric Oncology·2019· 2 cited
Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn’s Disease: A 9-Year Survival
Case Reports in Oncological Medicine·2019· 2 citedOpen Access
A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
Molecular Therapy — Oncolytics·2018· 56 citedOpen Access
Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohnʼs Disease: A Case with Prolonged Survival
The American Journal of Gastroenterology·2018
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer
Anticancer Research·2018· 7 citedOpen Access
Cancer of the Pancreas—Actual 5, 10, and 20+Year Survival
Surgical Clinics of North America·2017· 8 cited
Abstract CT061: Novel safety of high dose ascorbic acid and induction chemotherapy for high risk pancreatic cancer
Cancer Research·2017
page 1 of 15Next →

Frequent Co-authors

Carmel J. Cohen(8), Gunter Deppe(8), B Kabakow(6), Christian M. Kurbacher(5), Peter E. Andreotti(5), Ian A. Cree(5), Robert C. Wallach(4), James F. Holland(4), Donald M. Stablein(3), Robert J. Mayer(3), Lesley Stewart(3), Kristian Aabo(3), P I Adnitt(3), Malcolm Adams(3), V. Barley(3), Umberto Bianchi(3), Marc Buyse(3), Giorgio Bolis(3), Renzo Canetta(3), V Chylak(3)